Drugs@FDA: FDA-Approved Drugs
New Drug Application (NDA): 202171
Company: MATRIX LABS LTD
Company: MATRIX LABS LTD
Drug Name | Active Ingredients | Strength | Dosage Form/Route | Marketing Status | TE Code | RLD | RS |
---|---|---|---|---|---|---|---|
LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE | LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE | 300MG; 300MG; 200MG | TABLET; ORAL | None (Tentative Approval) | None | No | No |
Original Approvals or Tentative Approvals
Action Date | Submission | Action Type | Submission Classification | Review Priority; Orphan Status | Letters, Reviews, Labels, Patient Package Insert | Notes | Url |
---|---|---|---|---|---|---|---|
09/08/2011 | ORIG-1 | Tentative Approval | Type 4 - New Combination | STANDARD |
Letter (PDF)
|
Label is not available on this site. |
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2011/202171s000ltr.pdf |